Statistics

Total Visits

Views
FCGR2A/CD32A and FCGR3A/CD16A variants and EULAR response to tumor necrosis factor-alpha blockers in psoriatic arthritis: A longitudinal study with 6 months of followup26

Select a period of time:

Number of views in the range

Views
FCGR2A/CD32A and FCGR3A/CD16A variants and EULAR response to tumor necrosis factor-alpha blockers in psoriatic arthritis: A longitudinal study with 6 months of followup19

Views

Views
May 20243
June 20242
July 20243
August 20246
September 20242
October 20242
November 20241
Download CSV file
 untranslated
 untranslated

Top country views

Views
United States18
United Kingdom1
 

Top cities views

Views
Chicago2